<?xml version="1.0" encoding="UTF-8"?>
<ref id="B4-pharmaceutics-12-00388">
 <label>4.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ewer</surname>
    <given-names>K.J.</given-names>
   </name>
   <name>
    <surname>Lambe</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Rollier</surname>
    <given-names>C.S.</given-names>
   </name>
   <name>
    <surname>Spencer</surname>
    <given-names>A.J.</given-names>
   </name>
   <name>
    <surname>Hill</surname>
    <given-names>A.V.S.</given-names>
   </name>
   <name>
    <surname>Dorrell</surname>
    <given-names>L.</given-names>
   </name>
  </person-group>
  <article-title>Viral vectors as vaccine platforms: From immunogenicity to impact</article-title>
  <source>Curr. Opin. Immunol.</source>
  <year>2016</year>
  <volume>41</volume>
  <fpage>47</fpage>
  <lpage>54</lpage>
  <pub-id pub-id-type="doi">10.1016/j.coi.2016.05.014</pub-id>
  <pub-id pub-id-type="pmid">27286566</pub-id>
 </element-citation>
</ref>
